Rosanna McCalips

Jones Day (Washington DC)
Lawyer (Associate)

Rosanna McCalips has 10 years of experience defending pharmaceutical companies against antitrust lawsuits alleging a variety of exclusionary conduct. These proceedings have included sham Citizen Petition filings with the United States Food and Drug Administration (FDA), sham Hatch-Waxman Act patent infringement litigation, fraud on the United States Patent and Trademark Office (USPTO), abuse of FDA Risk Evaluation and Mitigation Systems (REMS) programs, and product hopping. She was a member of the defense team in one of the few pharmaceutical antitrust cases to go to trial, helping to obtain a full defense jury verdict for Sanofi-Aventis US LLC against a claim of monopolization based on the filing of an allegedly sham Citizen Petition with the FDA.


Linked authors

Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)


37 Bulletin

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act)


New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar (...)

Send a message